Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,081 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vision Disorder Clear all
Terminated Not applicable Interventional Results available

The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)

NCT02691455
View directory record Official record
Conditions
Glaucoma
Interventions
Baerveldt Glaucoma Implant 350-mm2 / BG101-350, Transscleral Diode Laser Cyclophotocoagulation, Ahmed Model FP7 Flexible Plate, Baerveldt Glaucoma Implant 250-mm2 / BG103-250
Device · Procedure
Lead sponsor
Robert Feldman
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional

Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes

NCT01744132
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus
Interventions
Aim 3: Contract
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00287521
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2Phase 3 Interventional

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00691717
View directory record Official record
Conditions
Open-angle Glaucoma, Oular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

NCT01430754
View directory record Official record
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

NCT03960866
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

NCT02023866
View directory record Official record
Conditions
Inherited Mitochondrial Disease, Including Leigh Syndrome
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 30, 2026, 6:14 PM EDT
Completed No phase listed Observational

Determinants of Compliance With Glaucoma Therapy

NCT00362622
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional

Tolerability of an Anesthesia-free Tonometer Tip

NCT06585423
View directory record Official record
Conditions
Glaucoma
Interventions
Sterile commercially available bandage contact lens, Medical grade silicone of a thickness >100 µm, Medical grade silicone of a thickness <100 µm with blur tint, Standard tip in conjunction with a topical anesthetic
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

NCT02371746
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
Drug
Lead sponsor
Envisia Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT00751127
View directory record Official record
Conditions
Glaucoma, Open Angle Glaucoma, Ocular Hypertension
Interventions
PhXA41, timolol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot

NCT00338208
View directory record Official record
Conditions
Glaucoma
Interventions
Training in the Use of Low Vision Devices
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 30, 2026, 6:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Optical Defocus to Stimulate Eye Elongation in Hyperopia

NCT00950924
View directory record Official record
Conditions
Hyperopia, Refractive Error
Interventions
Simultaneous Vision Bifocal Soft Contact Lenses, Single Vision Soft Contact Lenses
Device
Lead sponsor
Aller, Thomas A., OD
Other
Eligibility
5 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Bruno, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 30, 2026, 6:14 PM EDT
Terminated Not applicable Interventional

Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation

NCT04709679
View directory record Official record
Conditions
Glaucoma
Interventions
MicroPulse TransScleral CycloPhotoCoagulation
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry

NCT04360369
View directory record Official record
Conditions
Intraocular Pressure, Glaucoma
Interventions
IOP with Goldmann Applanation Tonometer, IOP with comparator ORA G3 and ic100 tonometers, IOP with Tono-Vera Tonometer
Device
Lead sponsor
Reichert, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

NCT02129075
View directory record Official record
Conditions
Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma, Ocular Melanoma, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 30, 2026, 6:14 PM EDT
Completed No phase listed Observational

Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study

NCT01728883
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Home vision monitoring using myVisionTrack®
Device
Lead sponsor
Vital Art and Science Incorporated
Industry
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional

Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2

NCT03192722
View directory record Official record
Conditions
Ocular Conditions Resulting in Visual Impairment
Interventions
Colored near reading glasses, Lighting as determined by LuxIQ/2 or OttLite Cobra
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

NCT05124275
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
40 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
10
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 30, 2026, 6:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Optic Nerve Head Strain as Biomarker for Glaucoma

NCT06240312
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Images of eye at 2 eye pressures
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 6:14 PM EDT